Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2011-06-10 | Mr. Faulkner has more than 25 years experience in developing and commercializing medical devices, drug and drug delivery systems, life science research tools, and molecular diagnostics. He received a bachelor’s degree in Industrial Relations from the University of North Carolina and a M.A. in Business Management from Webster University. |
| 2012-04-09 | Mr. Faulkner has more than 25 years experience in developing and commercializing medical devices, drug and drug delivery systems, life science research tools, and molecular diagnostics. |
| 2012-10-15 | Daryl J. Faulkner, director with stock options; no indication of software or programming skills. |
| 2013-04-29 | Mr. Faulkner received a degree in industrial relations from the University of North Carolina and a M.A. in business management from Webster University. |
| 2014-04-30 | Mr. Faulkner has more than 30 years’ experience in developing and commercializing medical devices, drug and drug delivery systems, life science research tools, and molecular diagnostics. |
| 2015-07-24 | Mr. Faulkner received a degree in industrial relations from the University of North Carolina and a M.A. in business management from Webster University. |
| 2016-02-29 | Daryl J. Faulkner (4) Includes 334 common shares held by the Daryl J. and Terri L. Faulkner Family Trust. Also includes options to purchase 15,001 shares at $50.07 per share, options to purchase 4,167 shares at $66.00 per share, options to purchase 1,667 shares at $17.70 per share, options to purchase 1,667 shares at $4.26 per shares, options to purchase 45,004 shares at $2.10 per share, options to purchase 26,000 shares at $2.04 per share, options to purchase 34,000 shares at $2.27 per share and options to purchase 53,000 shares at $1.89 per share. |
| 2016-10-17 | Mr. Faulkner has more than 30 years' experience in developing and commercializing medical devices, drug and drug delivery systems, life science research tools, and molecular diagnostics. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22